Lumida
/CABA
⌘K
Cabaletta Bio Inc

Cabaletta Bio Inc

CABA
$2.73USD-0.36%-0.01 today

MARKET CAP

462.9M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$4

AI Summary

Stalk
TrimMedium

In a Stage 4 decline with confirmed lower highs and lower lows, the medium-term bias remains bearish. Despite the Bearish Exhaustion pattern suggesting seller fatigue, price has only bounced into declining 9/21 EMA resistance without a decisive rejection. With no clear upside displacement, execution is deferred toward a trim on rallies into the 9 and 21 EMA zone and prior resistance region.

  • Phase 1/2 data show complete B-cell depletion by day 22 in all patients.
  • Management plans to meet FDA in early 2025 on registrational trial design.
  • Q2 2026 net loss of $51M with $44.4M R&D spend underscores cash burn.
Full analysis →
Insider Trades10 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jan 21, 2026BuyCABAMichael GerardGeneral Counsel6,600$2.27$462.9M-35.46%+58.72%$15.0KTrim
Jan 21, 2026BuyCABADavid J. ChangChief Medical Officer8,800$2.26$462.9M-35.46%+58.72%$19.9KTrim
Jan 21, 2026BuyCABAGwendolyn BinderPresident, Science & Tech.11,312$2.19$462.9M-35.46%+58.72%$24.8K+56.56%Trim
Jan 21, 2026BuyCABASteve GavelChief Commercial Officer22,170$2.27$462.9M-35.46%+58.72%$50.2KTrim
Jan 21, 2026BuyCABASteven NichtbergerPresident & CEO45,000$2.24$462.9M-35.46%+58.72%$100.8K+4.56%Trim
Jan 19, 2024SellCABAGwendolyn Binder22,000$10.30$462.9M-35.46%+58.72%$226.5K+0.00%10b5-1Trim
Dec 19, 2023SellCABAGwendolyn Binder22,000$11.45$462.9M-35.46%+58.72%$251.9K+0.00%10b5-1Trim
Nov 20, 2023SellCABAGwendolyn Binder22,000$9.41$462.9M-35.46%+58.72%$207.1K+0.00%10b5-1Trim
Oct 19, 2023SellCABAGwendolyn Binder22,000$7.18$462.9M-35.46%+58.72%$158.0K+0.00%10b5-1Trim
Sep 19, 2023SellCABAGwendolyn Binder22,000$9.29$462.9M-35.46%+58.72%$204.3K+0.00%10b5-1Trim